Pay in 4 interest-free payments of $5.89 Learn more
Ships within 48 hours · Estimated delivery Sep 22 - Sep 27
However, no clinical diagnostic test currently exists that would meaningfully guide prescribing decisions
Non-diabetic patients prescribed semaglutide have an increased likelihood of delayed gastric emptying and gallstones compared to those on other weight loss medications
Beyond weight loss, semaglutide improved a broad range of cardiometabolic parameters in ESSENCE [7] , consistent with prior data in T2DM and obesity [10,12]
Key evidence may include: A timeline showing symptom onset after starting Ozempic Medical diagnosis of gastroparesis or ileus Exclusion of other causes (such as diabetes, surgeries, or neurological conditions) Expert testimony from GI specialists Documentation that your prescribing doctor was not informed of the full risk Working with a firm like Morgan & Morgan, which has the resources to hire expert witnesses and comb through clinical trial data, can make a big difference in proving your case
